BOTTINI, Alberto
BOTTINI, Alberto
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers
2016-01-01 Roviello, Giandomenico; Milani, Manuela; Gobbi, Angela; Cappelletti, Maria Rosa; Zanotti, Laura; Senti, Chiara; Bottini, Alberto; Strina, Carla; Sigala, Sandra; Generali, Daniele
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease
2001-01-01 Fiorentino, C.; Berruti, A.; Bottini, A.; Bodini, M.; Brizzi, M. P.; Brunelli, A.; Marini, U.; Allevi, G.; Aguggini, S.; Tira, A.; Alquati, P.; Olivetti, L.; Dogliotti, L.
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
2010-01-01 Mele, Teresa; Generali, Daniele; Fox, Stephen; Brizzi, Maria Pia; Bersiga, Alessandra; Milani, Manuela; Allevi, Giovanni; Bonardi, Simone; Aguggini, Sergio; Volante, Marco; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian; Berruti, Alfredo
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
2015-01-01 Bazzola, L; Foroni, C; Andreis, D; Zanoni, V; R., Cappelletti M; Allevi, G; Aguggini, S; Strina, C; Milani, M; Venturini, S; Ferrozzi, F; Giardini, R; Bertoni, R; Turley, H; Gatter, K; Petronini, Pg; Fox, Sb; Harris, Al; Martinotti, M; Berruti, Alfredo; Bottini, Alberto; Reynolds, Ar; Generali, Daniele
Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]]
2016-01-01 Arpino, Grazia; Generali, Daniele; Sapino, Anna; Del Mastro, Lucia; Frassoldati, Antonio; de Laurentiis, Michelino; Pronzato, Paolo; Mustacchi, Giorgio; Cazzaniga, Marina; De Placido, Sabino; Conte, Pierfranco; Cappelletti, Mariarosa; Zanoni, Vanessa; Antonelli, Andrea; Martinotti, Mario; Puglisi, Fabio; Berruti, Alfredo; Bottini, Alberto; Dogliotti, Luigi
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response
2015-01-01 Generali, Daniele; Berruti, Alfredo; Cappelletti, Maria Rosa; Zanotti, Laura; Brugnoli, Giulia; Forti, Michela; Bedussi, Francesca; Vailati, Maria Elena; Milani, Manuela; Strina, Carla; Ardine, Mara; Aguggini, Sergio; Allevi, Giovanni; Ferrero, Giuseppina; Bertoni, Ramona; Bottini, Alberto; Harris, Adrian L.; Fox, Stephen B.
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer
2017-01-01 Milani, Manuela; Venturini, Sergio; Bonardi, Simone; Allevi, Giovanni; Strina, Carla; Cappelletti, Maria Rosa; Corona, Silvia Paola; Aguggini, Sergio; Bottini, Alberto; Berruti, Alfredo; Jubb, Adrian; Campo, Leticia; Harris, Adrian L.; Gatter, Kevin; Fox, Stephen B.; Generali, Daniele; Roviello, Giandomenico
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials
2016-01-01 Roviello, Giandomenico; Sigala, Sandra; Danesi, Romano; del Re, Marzia; Bonetta, Alberto; Cappelletti, Maria Rosa; Zanotti, Laura; Bottini, Alberto; Generali, Daniele
Neoadjuvant treatment approach: The rosetta stone for breast cancer?
2015-01-01 Generali, Daniele; Ardine, Mara; Strina, Carla; Milani, Manuela; Cappelletti, Maria Rosa; Zanotti, Laura; Forti, Michela; Bedussi, Francesca; Martinotti, Mario; Amoroso, Vito; Sigala, Sandra; Simoncini, EDDA LUCIA; Berruti, Alfredo; Bottini, Alberto
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial
2001-01-01 Donadio, M.; Manzin, E.; Berruti, A.; Bottini, A.; Gorzegno, G.; Danese, S.; Defabiani, E.; Sarobba, M. G.; Lorusso, V.; Castiglione, F.; Moro, G.; Bertetto, O.; Bumma, C.; Dogliotti, L.
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies.
2014-01-01 Berruti, Alfredo; Amoroso, Vito; Gallo, F; Bertaglia, V; Simoncini, EDDA LUCIA; Pedersini, Rebecca; Ferrari, L; Bottini, Alberto; Bruzzi, P; Sormani, Mp
Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer
2009-01-01 Generali, Daniele; Buffa, Francesca M.; Berruti, Alfredo; Brizzi, Maria P.; Campo, Leticia; Bonardi, Simone; Bersiga, Alessandra; Allevi, Giovanni; Milani, Manuela; Aguggini, Sergio; Papotti, Mauro; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian L.; Fox, Stephen B.
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer
2006-01-01 Generali, D.; Fox, S. B.; Berruti, A.; Brizzi, M. P.; Campo, L.; Bonardi, S.; Wigfield, S. M.; Bruzzi, P.; Bersiga, A.; Allevi, G.; Milani, M.; Aguggini, S.; Dogliotti, L.; Bottini, A.; Harris, A. L.
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials
2016-01-01 Roviello, Giandomenico; Sigala, Sandra; Sandhu, Shahneen; Bonetta, Alberto; Cappelletti, Maria Rosa; Zanotti, Laura; Bottini, Alberto; Sternberg, Cora N.; Fox, Stephen B.; Generali, Daniele
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
2011-01-01 Fox, Stephen B; Generali, Daniele; Berruti, Alfredo; Brizzi, Maria P.; Campo, Leticia; Bonardi, Simone; Bersiga, Alessandra; Allevi, Giovanni; Milani, Manuela; Aguggini, Sergio; Mele, Teresa; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers | 1-gen-2016 | Roviello, Giandomenico; Milani, Manuela; Gobbi, Angela; Cappelletti, Maria Rosa; Zanotti, Laura; Senti, Chiara; Bottini, Alberto; Strina, Carla; Sigala, Sandra; Generali, Daniele | |
| Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease | 1-gen-2001 | Fiorentino, C.; Berruti, A.; Bottini, A.; Bodini, M.; Brizzi, M. P.; Brunelli, A.; Marini, U.; Allevi, G.; Aguggini, S.; Tira, A.; Alquati, P.; Olivetti, L.; Dogliotti, L. | |
| Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients | 1-gen-2010 | Mele, Teresa; Generali, Daniele; Fox, Stephen; Brizzi, Maria Pia; Bersiga, Alessandra; Milani, Manuela; Allevi, Giovanni; Bonardi, Simone; Aguggini, Sergio; Volante, Marco; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian; Berruti, Alfredo | |
| Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. | 1-gen-2015 | Bazzola, L; Foroni, C; Andreis, D; Zanoni, V; R., Cappelletti M; Allevi, G; Aguggini, S; Strina, C; Milani, M; Venturini, S; Ferrozzi, F; Giardini, R; Bertoni, R; Turley, H; Gatter, K; Petronini, Pg; Fox, Sb; Harris, Al; Martinotti, M; Berruti, Alfredo; Bottini, Alberto; Reynolds, Ar; Generali, Daniele | |
| Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]] | 1-gen-2016 | Arpino, Grazia; Generali, Daniele; Sapino, Anna; Del Mastro, Lucia; Frassoldati, Antonio; de Laurentiis, Michelino; Pronzato, Paolo; Mustacchi, Giorgio; Cazzaniga, Marina; De Placido, Sabino; Conte, Pierfranco; Cappelletti, Mariarosa; Zanoni, Vanessa; Antonelli, Andrea; Martinotti, Mario; Puglisi, Fabio; Berruti, Alfredo; Bottini, Alberto; Dogliotti, Luigi | |
| Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response | 1-gen-2015 | Generali, Daniele; Berruti, Alfredo; Cappelletti, Maria Rosa; Zanotti, Laura; Brugnoli, Giulia; Forti, Michela; Bedussi, Francesca; Vailati, Maria Elena; Milani, Manuela; Strina, Carla; Ardine, Mara; Aguggini, Sergio; Allevi, Giovanni; Ferrero, Giuseppina; Bertoni, Ramona; Bottini, Alberto; Harris, Adrian L.; Fox, Stephen B. | |
| Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer | 1-gen-2017 | Milani, Manuela; Venturini, Sergio; Bonardi, Simone; Allevi, Giovanni; Strina, Carla; Cappelletti, Maria Rosa; Corona, Silvia Paola; Aguggini, Sergio; Bottini, Alberto; Berruti, Alfredo; Jubb, Adrian; Campo, Leticia; Harris, Adrian L.; Gatter, Kevin; Fox, Stephen B.; Generali, Daniele; Roviello, Giandomenico | |
| Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials | 1-gen-2016 | Roviello, Giandomenico; Sigala, Sandra; Danesi, Romano; del Re, Marzia; Bonetta, Alberto; Cappelletti, Maria Rosa; Zanotti, Laura; Bottini, Alberto; Generali, Daniele | |
| Neoadjuvant treatment approach: The rosetta stone for breast cancer? | 1-gen-2015 | Generali, Daniele; Ardine, Mara; Strina, Carla; Milani, Manuela; Cappelletti, Maria Rosa; Zanotti, Laura; Forti, Michela; Bedussi, Francesca; Martinotti, Mario; Amoroso, Vito; Sigala, Sandra; Simoncini, EDDA LUCIA; Berruti, Alfredo; Bottini, Alberto | |
| Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial | 1-gen-2001 | Donadio, M.; Manzin, E.; Berruti, A.; Bottini, A.; Gorzegno, G.; Danese, S.; Defabiani, E.; Sarobba, M. G.; Lorusso, V.; Castiglione, F.; Moro, G.; Bertetto, O.; Bumma, C.; Dogliotti, L. | |
| Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. | 1-gen-2014 | Berruti, Alfredo; Amoroso, Vito; Gallo, F; Bertaglia, V; Simoncini, EDDA LUCIA; Pedersini, Rebecca; Ferrari, L; Bottini, Alberto; Bruzzi, P; Sormani, Mp | |
| Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer | 1-gen-2009 | Generali, Daniele; Buffa, Francesca M.; Berruti, Alfredo; Brizzi, Maria P.; Campo, Leticia; Bonardi, Simone; Bersiga, Alessandra; Allevi, Giovanni; Milani, Manuela; Aguggini, Sergio; Papotti, Mauro; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian L.; Fox, Stephen B. | |
| Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer | 1-gen-2006 | Generali, D.; Fox, S. B.; Berruti, A.; Brizzi, M. P.; Campo, L.; Bonardi, S.; Wigfield, S. M.; Bruzzi, P.; Bersiga, A.; Allevi, G.; Milani, M.; Aguggini, S.; Dogliotti, L.; Bottini, A.; Harris, A. L. | |
| Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials | 1-gen-2016 | Roviello, Giandomenico; Sigala, Sandra; Sandhu, Shahneen; Bonetta, Alberto; Cappelletti, Maria Rosa; Zanotti, Laura; Bottini, Alberto; Sternberg, Cora N.; Fox, Stephen B.; Generali, Daniele | |
| The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen | 1-gen-2011 | Fox, Stephen B; Generali, Daniele; Berruti, Alfredo; Brizzi, Maria P.; Campo, Leticia; Bonardi, Simone; Bersiga, Alessandra; Allevi, Giovanni; Milani, Manuela; Aguggini, Sergio; Mele, Teresa; Dogliotti, Luigi; Bottini, Alberto; Harris, Adrian L. |